Ferring Pharmaceuticals provides human growth hormone hGH (somatropin) for the treatment of children with a deficiency of the hormone and girls with Turner’s syndrome.

One in 2,500 to 5,000 children is born with deficient growth hormone production that can be helped from treatment with supplemental growth hormone.  Some of these children require continued supplements into adulthood.

Ferring is committed to helping such patients by investing in research to identify and develop more user-friendly and efficient methods of treatment.

Growth hormone therapy
Growth hormone therapy is a long-term treatment that currently needs to be administered on a nightly basis directly into the skin for it to be absorbed into the blood stream in an active form. 

Ferring’s somatropin product, ZOMACTON®, produced using DNA recombinant technology is identical to growth hormone produced by the human body.  For maximum benefit and prevention of long-term complications associated with deficient growth hormone production it is essential that patients do not miss any of their prescribed daily injections.

No-needle injections
Ferring’s awareness of the negative impact that injections have on a patient’s on-going acceptance of a treatment and the impact on its ultimate success has led to Ferring offering a way of making injections more acceptable and agreeable.

Ferring offers a unique no-needle delivery system for growth hormone, ZOMAJET® 2 VISION, a user-friendly device, that is intended to be less intimidating and therefore encouraging regular use.